After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Truist Securities Downgrades IGM Biosciences (IGMS) to Hold
October 1, 2024 6:52 AM EDTTruist Securities analyst Asthika Goonewardene downgraded IGM Biosciences (NASDAQ: IGMS) from Buy to Hold with a price target of $12.00 (from $24.00).
The analyst comments "What started as a side-hustle is now a full scale pivot - IGMS is now solely focused on autoimmune... More
IGM Biosciences (IGMS) PT Lowered to $17 at RBC Capital
October 1, 2024 6:32 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on IGM Biosciences (NASDAQ: IGMS) to $17.00 (from $20.00) while maintaining a Outperform rating.
The analyst comments "While discontinuation of aplitabart is disappointing, evolution into a pure-play autoimmune company with T-cell engagers should streamline... More
Jefferies Reiterates Buy Rating on IGM Biosciences (IGMS)
October 1, 2024 6:16 AM EDTJefferies analyst Roger Song reiterated a Buy rating and $48.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "We caught up with mgmt. Co has focused on autoimmune franchise for a while, along with partner Sanofi's recent strategic shift, so... More
Morgan Stanley Reiterates Equalweight Rating on IGM Biosciences (IGMS)
October 1, 2024 6:09 AM EDTMorgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)
The analyst comments "IGM announced multiple updates, including a pipeline reprioritization focused on T cell engagers for autoimmune diseases and discontinuation of oncology development,... More
